L-myc Gene Expression in Canine Fetal Fibroblasts Promotes Self-Renewal Capacity but Not Tumor Formation

Canines are useful in mammalian preclinical studies because they are larger than rodents and share many diseases with humans. Canine fetal fibroblast cells (CFFs) are an easily accessible source of somatic cells. However, they are easily driven to senescence and become unusable with continuous in vitro culture. Therefore, to overcome these deficiencies, we investigated whether tetracycline-inducible L-myc gene expression promotes self-renewal activity and tumorigenicity in the production of induced conditional self-renewing fibroblast cells (iCSFCs). Here, we describe the characterization of a new iCSFC line immortalized by transduction with L-myc that displays in vitro self-renewal ability without tumorigenic capacity. We established conditionally inducible self-renewing fibroblast cells by transducing CFF-3 cells with L-myc under the tetracycline-inducible gene expression system. In the absence of doxycycline, the cells did not express L-myc or undergo self-renewal. The iCSFCs had a fibroblast-like morphology, normal chromosome pattern, and expressed fibroblast-specific genes and markers. However, the iCSFCs did not form tumors in a soft agar colony-forming assay. We observed higher expression of three ES modules (core pluripotency genes, polycomb repressive complex genes (PRC), and MYC-related genes) in the iCSFCs than in the CFF-3 cells; in particular, the core pluripotency genes (OCT4, SOX2, and NANOG) were markedly up-regulated compared with the PRC and MYC module genes. These results demonstrated that, in canine fetal fibroblasts, L-myc tetracycline-inducible promoter-driven gene expression induces self-renewal capacity but not tumor formation. This study suggests that L-myc gene-induced conditional self-renewing fibroblast cells can be used as an in vitro tool in a variety of biomedical studies related to drug screening.


Introduction
In 2006, somatic cells were reprogrammed into induced pluripotent stem cells (iPSCs) by 64 viral transduction with 4 transcription factors: POU5F1 (Oct3/4), SOX2, MYC (Cmyc), and KLF4 [1]. In subsequent years, iPSCs were generated from various cell sources, including mouse embryonic fibroblasts, adult mouse tail fibroblasts, and adult human dermal fibroblasts, by retroviral transduction with the 4 key transcription factors [1,2]. These iPSCs show similar characteristics to Embryonic Stem Cells (ESCs) regarding morphology, proliferation, activation of both X chromosomes, pluripotency gene expression and teratoma formation [2][3][4][5]. In an attempt to avoid the ethical and legal issues associated with human tissue biopsies, iPSCs have been generated from fibroblasts of diverse species, such as canine, pig, and rat [6][7][8].In veterinary medicine, canines are used in mammalian preclinical studies because they are larger than rodents and share many diseases with humans. Canine somatic cell-derived iPSCs have been established and characterized [8][9][10]. In animal models, reprogrammed iPSCs show ESC-like characteristics without chromosomal abnormalities [11]. Recently, various biomedical investigations on in vitro drug screening and mammalian preclinical cell therapy studies have characterized different mammalian somatic cell-derived ESC-like iPSCs.
The transcription factor MYC is induced during cell proliferation and tumor formation. The most important function of MYC is to control cell proliferation, including the regulation of cell-matrix interactions, protein and DNA synthesis, and cell cycle progression [12], which stimulates cyclin-cyclin-dependent kinase complexes [13]. MYC also maintains selfrenewal and suppresses the expression of differentiation genes to maintain stemness [14]. Moreover, MYC enhances reprogramming efficiency and shows consistently high expression in reprogrammed colonies [15]; it inhibits both cell quiescence as well as terminal differentiation [16]. Thus, MYC is a multipotent factor that influences many aspects of normal cell behavior related to chromatin remodeling [17]. The MYC proto-oncogene family comprises several isoforms, including C-myc, MYCN (N-myc), and MYCL (L-myc). Some studies have reported that C-myc plays a central role in tumorigenicity and self-renewal during iPSC generation and normal embryonic development [1,8,11,18].N-myc is similar to C-myc in domain structure and is a common factor implicated in human cancer [19]. V-myc is the viral homolog of C-myc and was first identified in an acute avian retrovirus (MC29) [20]. V-myc was previously used to generate the stable human neural stem cell line HB1.F3 and derivative cell lines, which undergo unlimited proliferation and facilitate functional recovery in a mouse stroke model [21]. L-myc has a shorter amino acid sequence in the N-terminal domain than C-myc [22]. L-myc may be a useful factor for promoting self-renewal because it induces less proliferation and tumorigenicity in transformed cells than does C-myc [23].
Therefore, we explored in canine fetal fibroblast-3 (CFF-3) cells whether stable, conditionally induced self-renewing fibroblast cells (iCSFCs) could be established with selfrenewal activity and low tumorigenicity via transduction with only 1 retroviral vector carrying the tetracycline-inducible promoter-driven L-myc gene. Here we present the characterization of a new iCSFCs line immortalized by transduction with tetracycline-inducible promoter-driven L-myc that displays self-renewal and non-tumorigenic capabilities in vitro.

Ethics Statement
CFF-3 female begle fetus cell was obtained from the National Institute of Animal Science (RDA). Use of laboratory animals (female begle fetus) for the study was approved by the National Institute of Animal Science (RDA) Institutional Animal Care Committee (IACUC; Certificate 2016-204) and was accordance with the Guide for the care and use of laboratory animals as published by the United States National Institute of Health.

Generation of iCSFCs
To induce the proliferation of primary fibroblast cells, we inserted proliferationinducing genes with a lentiviral vector; transcription of the genes was driven by a tetracycline-inducible promoter, which drove the transcription of the target genes in the presence of the tetracycline derivative doxycycline (Clontech, Palo Alto, CA, USA). The human L-myc gene was inserted into the BamHI sites of a lentiviral vector, pDINEO, which contained the tetracycline-driven promoter and a neomycin selective marker. The generated lentivirus vectors were designated pDINEO-L-myc.

Cytogenetic Analysis
Chromosome identification for somatic cell donors was performed using high-resolution GTG banding. The karyotypes of the iCSFCs (passage 20) were identified using cytogenetic analysis with Giemsa stain (Sigma-Aldrich), and processed via the manufacturer's protocol.

Cell Growth and Cell Cycle Analysis
To determine the cell growth rates of iCSFCs, we cultured CFF-3 cells and iCSFCs in the presence or absence of doxycycline. To eliminate the doxycycline effects on proliferation, the cells were cultured in the absence of doxycycline for 7 days. The cell growth rate was determined using the Muse Count and Viability Assay Kit (MCH100102; Millipore, Billerica, MA, USA), according to the manufacturer's instructions, with a Muse Cell Analyzer. Briefly, the cells were suspended in phosphate-buffered saline (PBS) and mixed with Muse Count and Viability working solution. The cells were analyzed using the Muse Cell Analyzer once every 2 days for 2 weeks.
The cell cycle status of the cells was analyzed using the Muse Cell Cycle Assay Kit (MCH100106; Millipore) according to the manufacturer's instructions. The suspended cells were fixed in 70% ice-cold ethanol at −20°C for 3 h. After they were washed with PBS, the cell pellets were resuspended and incubated in 200 µL Muse Cell Cycle reagent. The cell cycle phase distributions were analyzed with the Muse Cell Analyzer.

Tumor Formation Assay
Tumor formation ability was determined using a soft agar colony-forming assay. We coated each well of a 6-well plate with 2 mL bottom agar mixture (DMEM, 10% FBS, and 0.6% agar). After the bottom layer solidified, we added 2 mL of top agar mixture (DMEM, 10% FBS, and 0.4% agar) containing cells (2.5 × 103/mL) to each well. The cultures were incubated at 37°C in an incubator with a 5% CO 2 atmosphere. Every 5 days, the doxycycline-free growth medium or doxycycline-containing growth medium as layered gently over the cultures. Colony formation was monitored daily using a light microscope. The colonies formed in soft agar were cultured for 14 days, stained with 0.5 mL 0.1% crystal violet (Sigma-Aldrich) for 1 h, then photographed using an Olympus microscope at 40× magnification.

Quantitative RT-PCR
We performed quantitative RT-PCR (qPCR) with the oligonucleotide primers in Supplementary Table S2. The amplifications were carried out in a total volume of 20 µL, containing 10 µL Rotor-Gene SYBR Green PCR Kit (204074; QIAGEN), 2 µL of the relevant PCR primers, 7 µL nuclease-free water, and 1 µL DNA template. The thermal cycling conditions included an initial step at 95°C for 5 min, followed by 40 cycles consisting of 95°C for 20 s and 60°C for 30 s. Amplifications were performed using a Rotor-Gene Q system (QIAGEN); we calculated the ∆∆Ct data with the Rotor-Gene Q Series software (QI-AGEN). All qPCR runs included template-free negative controls. qRT-PCR was performed at triplicate for each replicate and repeated three times for statistical analysis.

Statistical Analysis
All experiments were repeated 3 times. Student's t-test was used to assess statistical significance with thresholds of p < 0.05 and p < 0.01 for significant and highly significant differences, respectively (CFF-3 versus iCSFCs). We analyzed the data with SigmaPlot version 12 (Systat Software, San Jose, CA, USA).

Generation of iCSFCs
A representative clonal iCSFC line was obtained after gene transduction into primitive CFF-3 cells using the pDINEO lentiviral vector encoding L-myc, which induced L-myc expression in the presence of doxycycline ( Figure 1A). After transduction, iCSFCs were selected for 2-3 weeks in G418. The established iCSFC line was stably maintained for more than 20 passages, then characterized. The CFF-3 cells and iCSFCs in the growth medium were observed adherent, fibroblast-like morphologies, with flat, polygonal shapes by an optical microscope. The iCSFCs remained consistent over long-term culture of at least 70 passages, without morphological changes or chromosomal abnormalities ( Figure 1B). Upon Giemsa staining and cytogenetic analysis, iCSFCs had a normal karyotype with 78 chromosomes and 2 X sex chromosomes ( Figure 1C).

L-myc Expression Improved the Proliferation of iCSFCs, Not Promote Tumor Formation
To verify the doxycycline-induced L-myc expression in iCSFCs, we examined the expression levels of L-myc in CFF-3 and iCSFCs in the presence of doxycycline. We found that L-myc was expressed in iCSFCs, but not in CFF-3 cells upon doxycycline treatment ( Figure 2A). In addition, to confirm the duration of the doxycycline-induced effects in iCSFCs, we examined the L-myc expression pattern at various time points after doxycycline removal. RT-PCR showed that the expression of L-myc in iCSFCs decreased in a timedependent manner in the absence of doxycycline ( Figure 2B). Subsequently, to investigate whether iCSFCs growth rates increased in a doxycycline-dependent manner, we counted the number of iCSFCs in the absence or presence of doxycycline, along with CFF-3 cells as a control, using the Muse™ Count and Viability Assay Kit at 0, 1, 3, 5, and 7 days. As shown in Figure 2C, treatment with doxycycline caused a marked increase in the proliferation rate of iCSFCs compared with iCSFCs cultured in the absence of doxycycline and CFF-4 cells. Doxycycline treatment of iCSFCs (1 × 10 4 /mL at day) for 7 days resulted in significantly increased cell numbers by approximately 31-folds (5933 ± 33) compared with untreated iCSFCs (186. 33 ± 7.22).
To determine whether the increase in cell numbers was due to proliferation, we analyzed cell cycle progression with a Muse™ Cell Cycle Assay Kit in the presence and absence of doxycycline. The proportion of G2/M phase iCSFCs was low on day 4 (9% ± 4) and day 7 (2% ± 2) in the absence of doxycycline, whereas doxycycline treatment significantly increased this percentage on both day 4 (23% ± 5) and day 7 (24% ± 2) ( Figure 2D-I). Complementarily, the proportion of G0/G1 phase cells was higher in the absence of doxycycline.
To investigate whether iCSFCs formed tumors in vitro, we performed a soft agar colony-forming assay. We observed less growth and fewer iCSFCs in the absence of doxycycline than in the presence of doxycycline ( Figure 2C). We were unable to observe tumor formation, and all the cells grew independently. These results indicated that Lmyc expression in iCSFCs in the presence of doxycycline induced proliferation but did not promote colony formation on soft agar ( Figure 3). Thus, these results suggested that, upon doxycycline treatment, L-myc expression in iCSFCs conferred the capacity for continuous cell division, resulting in increased cell proliferation. However, L-myc expressed iCSFCs did not promote formation.

Elevated Expression of Three ES Cell Modules (CORE, PRC, and MYC) in iCSFCs
Fundamental transcriptional subnetworks including core pluripotency factor (CORE), polycomb repressive complex factor (PRC), and MYC-related factors (MYC) modules have been shown to participate in preservation of the pluripotency and self-renewability of embryonic stem cells (ESCs) [24]. To determine the molecular signature of the iCSFCs, we used the 3 regulatory gene sets for comparative analyses of gene network activation. The expression levels of the CORE, PRC, and MYC module genes were examined by qPCR analysis ( Figure 5A, Supplementary Table S2). The CORE module genes are regulated by specific transcription factors in ESCs, including POU5F1(OCT4), SOX2, NANOG, and KLF4 [25]. In iCSFCs, we observed that the expression of 3 genes in the CORE module (OCT4, SOX2, and NANOG) was increased, but not increased expression of KLF4, compared to CFF-3 cells ( Figure 5B). The PRC module genes are known to be upregulated in fibroblasts and comprise genes inactivated in differentiated cells during development [26]. The iCSFCs showed elevated expression of 8 genes (CBX1, RING1A, RING1B, YY1, EED, EZH2, RBBP4, and SUZ12) and lower expression of 3 genes (BMI1, RYBP, and EZH1) in the PRC module compared with CFF-3 cells ( Figure 5C). iCSFCs showed higher expression of 11 genes (ACT1, ARP4, EAF1, EAF2, EAF3, EAF6, EAF7, ESA1, SWC4, TRA1, and YAF9) and reduced expression of 5 genes (EPL1, MAX, C-myc, L-myc, and V-myc) in the MYC module compared to CFF-3 cells ( Figure 5D). The core pluripotency genes (OCT4, SOX2, and NANOG) were markedly up-regulated to a much greater extent than PRC and MYC module genes in iCSFCs ( Figure 5A). These results suggested that iCSFCs had increased expression of CORE, PRC, and MYC module genes compared with CFF-3 cells. However, we did not observe teratoma formation in a long-term teratoma assay as an in vivo assessment of pluripotency (data not shown).

Discussion
Canine fetal fibroblast cells (CFFs) are the preferred candidate donor cells for the production of transgenic dogs using somatic cell nuclear transfer, mainly due to their excellent proliferative capacity, developmental ability, and ease of genetic modification [27]. CFFs can be easily manipulated by various techniques such as genetic engineering [27], but they are easily driven to senescence and become unusable with continuous in vitro culture [28][29][30]. In this study, we produced a new conditionally induced self-renewing fibroblast cell (iCSFCs) line immortalized by tetracycline-inducible L-myc gene expression that displays in vitro self-renewal ability. These iCSFCs showed a fibroblast-like morphology and expressed fibroblast-specific genes. In addition, three ES modules (core pluripotency genes, polycomb repressive complex genes (PRC), and MYC-related genes) showed elevated expression levels compared with CFFs, as shown in Supplementary  Figure S1. However, these cells did not display tumor or teratoma formation. These findings suggest a gene expression profile of iCSFCs more similar to that of stem cells and mouse embryonic fibroblasts than cancer cells. The present study suggests the utility of L-myc gene-induced iCSFCs as an in vitro tool in a variety of biomedical studies related to drug screening.
A stable karyotype, which can be analyzed by G-banded karyotyping, is considered a key standard for establishing therapeutically viable ESCs [31]. In human ESCs, genomic abnormalities can accumulate during long-term culture [3,4]. Previously observed genomic abnormalities demonstrated the chromosomal instability of canine induced pluripotent stem cells (ciPSCs) resulting in genomic abnormalities on chromosomes 4, 8, 13, and 16 following prolonged culture [32]. In contrast, the iCSFCs in the present study maintained normal chromosomal patterns after extensive passage ( Figure 1B,C). These results suggest that iCSFCs have superior chromosomal stability compared with ciPSCs. One possible explanation is that although induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) share many common features, including similar morphologies and in vitro gene expression profiles, several previous studies have reported a much lower genomic stability in iPSCs than in ESCs [33,34]. The relatively poor genomic stability of iPSCs and their high rate of tumorigenesis in vivo appear to be due, at least in part, to their low fidelity of DNA damage repair. As shown in Figure 3, the iCSFCs in this study did not form tumors in a soft agar colony-forming assay. Therefore, these results indicate that we successfully produced a new iCSFCs line with self-renewal ability and chromosomal stability.
Fibroblast-derived CFF-3 cells and iCSFCs both expressed various fibroblast markers. Thus, it is possible that the new iCSFCs maintain fibroblast properties in vitro ( Figure 4). However, as shown in Figure 4A, SOX5 was expressed in the new iCSFCs, a further indication of self-renewal ability, but not in the fibroblast-derived CFF-3 cells. It was reported that both SOX5 and SOX6 are required for optimal proliferation [35]. SOX5 expression is elevated in progenitor cells, whereas SOX5 downregulation in post-mitotic cells is necessary for progression of the differentiation program [36]. These previous studies of SOX5 expression are consistent with our results. SOX6 mediates p53 stabilization and has tumor inhibitory activities in vitro and in vivo [37]. Indeed, SOX6 has been described as a tumor suppressor gene in various cancers [38]. SOX6 directly activates transcription of aggrecan (Acan) [39] and expression of MMP12 in cancer tissue [40]. In the present study, we did not observe detectable levels of SOX6, aggrecan (Acan) or MMP12 in the new iCSFCs ( Figure 4A). These results suggest that the new iCSFCs maintain fibroblast properties and do not have tumor activity in vitro.
Recent studies on canine fetal and adult fibroblast cells have described the generation of ciPSCs by retroviral transduction of donor cells with transcription factors in the presence of proliferation stimulators, chemical inhibitors, or DNA methyltransferase inhibitors in order to maintain self-renewal [10,11,32,41,42]. The establishment of iPSCs by retroviral transduction of MYC into progenitor cells has proven to be a more practical approach. Several previous studies reported tumor formation by iPSCs overexpressing MYC in vitro and in vivo after transduction or transplantation, respectively [18,41]. MYC is crucial for promoting self-renewal in somatic cells during the transition to a pluripotent state [16,43], but it also has the potential to induce tumorigenic activity. L-MYC promotes cell proliferation but poses a lower oncogenic risk than other MYC family members. L-MYC has significantly lower transformation activity in cultured cells compared with other MYC members [22,44], and only a small number of human cancers have been associated with the aberrant expression of L-MYC [45]. Human stem cells engineered to express L-MYC have shown self-renewal and multipotent differentiation capacities in the absence of tumorigenic properties, and human fibroblasts retrovirally transduced with L-myc also display normal karyotypes [46]. Thus, similar to the results reported by Nakagawa et al. (2010) [46], we used L-myc to generate immortalized iCSFC lines based on its low tumorigenicity. As shown in Figures 2 and 3, we established iCSFCs from donor cells transduced with a single copy of L-myc to conditionally induce self-renewal using a tetracycline-inducible gene expression system, which did not promote tumor formation. As a further step, these iCSFC lines immortalized with L-myc could represent a safer option for effectively generating canine iPSCs (ciPSCs) with preserved pluripotency and differentiation properties in vitro and in vivo upon the introduction of various transcription factors.
Self-renewal and pluripotency in iPSCs are promoted by the transcription factors POU5F1(Oct4), SOX2, C-myc, and KLF4 [1]; genome-wide regulatory networks have been shown to participate in the preservation of ESC status. A conceptual framework of regulatory networks has recently been developed, which includes protein interactions supporting mouse ESC status, through targeted studies of core pluripotency factors (CORE), polycomb complex factors (PRC), and MYC-related factors (MYC) [47]. Many genes have been categorized into these 3 transcriptional sub-networks, which are related to specific cellular proliferation patterns [24]. Oct4, Sox2, and Nanog are well-known factors thought to be the master regulators of ES cell pluripotency [2], and Klf4 is known to induce growth arrest and inhibit cell proliferation by regulating the expression of key cell cycle genes [48,49]. Our results are consistent with those of previous studies of CORE module genes. As shown in Figure 5B, we observed increased expression of 3 CORE module genes (OCT4, SOX2, NANOG) in iCSFCs, but the other CORE module gene (KLF4) was decreased compared to CFF-3 cells.
Polycomb group (PcG) proteins are epigenetic repressors essential for cell differentiation and development [50]. A previous study connected PcG protein function with several key processes governing somatic stem cell activity [50]. The two best-characterized PcG complexes, polycomb repressive complex 1 (PRC1) (CBX1, RING1A, RING1B, BMI1, YY1, RYBP, etc.) and PRC2 (SUZ12, EZH2, EZH1, EED, RBBP4, etc.), are required for maintaining the stemness of embryonic stem cells and many types of adult stem cells. Figure 5C compares the expression of PRC module genes in iCSFCs and CFF-3 cells. The iCSFCs had higher expression of 8 PRC module genes (CBX1, RING1A, RING1B, YY1, EED, EZH2, RBBP4, and SUZ12) and lower expression of 3 genes (BMI1, RYBP, and EZH1) than CFF-3 cells. The PRC module genes were more highly expressed in iCSFCs than in CFF-3 cells, with EZH2 showing the greatest increase. However, EZH1 was decreased. EZH2 is the functional enzymatic component of PRC2 and is required for healthy embryonic development through epigenetic maintenance of genes responsible for regulating development and differentiation [51]. EZH2 is responsible for the methylation activity of PRC2, and the complex also contains proteins required for optimal functionality of EED and SUZ12 [52]. EZH1 is more abundant in non-proliferative adult organs, while EZH2 expression is tightly associated with proliferation, as evidenced in the aging mouse kidney [53]. Overexpression of Ring1 and YY1 binding protein (RYBP) inhibited anaplastic thyroid cancer cell proliferation and invasion [54]. Therefore, our result showing decreased expression of RYBP and EZH1 with increased EZH2 expression in iCSFCs with self-renewal ability was in concordance with this previous study. BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) has been reported as an oncogene through its regulation of the cell cycle inhibitors p16 and p19 [55]. In the present study, BMI1 showed decreased expression. As shown in Figure 3, the iCSFCs did not form tumors in a soft agar, and this is potentially related to their decreased BMI1 expression. We also observed increased expression of MYC module genes in iCSFCs compared to CFF-3 cells. The MYC module genes stimulate cellular metabolism by activating genes that are controlled by C-myc and its related proteins [24]. Our data demonstrate that most MYC module genes are expressed in the iCSFCs. However, as shown in Figure 5D, C-myc, L-myc, and V-myc were decreased. The C-myc protein can act as a modulator of its own gene transcription, and our results are consistent with the hypothesis that a negative feedback mechanism contributes to genetic the regulation of C-myc in normal cells [56]. Thus, the decreased C, L, and V-myc in L-myc-expressing iCS-FCs may be the result of a negative feedback mechanism. Similar to the results presented in supplemantary Figure S1, previous studies [24,57] reported that CORE module gene levels and MYC module gene levels are increased in ESCs, whereas PRC module genes are expressed at low levels. Mouse embryonic fibroblasts express low levels of CORE and MYC module genes but high levels of the PRC module genes. Cancer cells have low expression of CORE and PRC module genes but high expression of MYC module genes [24]. We found that the expression of CORE module genes (OCT4, SOX2, and NANOG) in iCSFCs was markedly up-regulated compared with PRC and MYC module genes, indicating that CORE module genes were increased by somatic reprogramming of iCSFCs. CORE module genes are key developmental homeodomain proteins that are suppressed in differentiated cells; self-renewal is sustained by a combinatorial network involving these genes [58]. Therefore, these results indicated that the iCSFCs had an expression pattern more similar to ESCs than fibroblasts and cancer cells.
Dogs have great potential as an animal model for human genetic diseases compared to the more widely accepted rodent models used in preclinical research [59,60]. Canines have been used to support preclinical studies because they are larger and more accurately reflect human responses to diseases than rodents. The risks associated with the application of new therapies may be better represented in canine [57,61,62] than in mouse [63,64] models, and safety and efficacy studies in dogs should therefore be considered before conducting clinical trials in humans [65]. Canines share many physiologic features with humans, as well as various hereditary diseases, such as van den Ende-Gupta syndrome, Raine syndrome, neurodegenerative disorders and inherited musculoskeletal diseases [66][67][68]. Thus, canine models may support the development of new therapeutic approaches for human diseases, and iCSFCs may be used for human disease models in the near future.

Conclusions
The use of an L-myc transduction system for iPSCs may be beneficial for future clinical applications and reprogramming research. Moreover, iCSFCs can be used in a variety of biomedical research studies related to cell therapy and drug screening. These cells can also be used as the basis for establishing alternative cellular models for several animal-or human-specific diseases.
Supplementary Materials: The following are available at https://www.mdpi.com/2073-4409/10 /8/1980/s1, Figure S1: The three sets of genes that are activated or repressed in iCSFCs, Table S1: PCR Primer Sequences for Cell Type-Fibroblast Markers (All Canis lupus familiaris), Table S2: qPCR Primer Sequences for CORE, PRC, MYC module Markers (All Canis lupus familiaris).  Data Availability Statement: The datasets and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest:
The authors declare that they have no competing interests.
Sample Availability: Samples of the compounds are available from the authors.

Abbreviations
The following abbreviations are used in this manuscript: